medigraphic.com
ISSN 1561-3070 (Electronic)

2022, Number 2

<< Back Next >>

Rev Cub Oftal 2022; 35 (2)

Corneal epithelial dysplasia

Brizuela CY, Pérez PZ, León RY, Hernández FY, Benítez MMC

Language: Spanish
References: 12
Page: 1-6
PDF size: 179.16 Kb.


ABSTRACT

Corneal-conjunctival intraepithelial neoplasms are premalignant, poorly demarcated, slow-growing lesions with low malignant potential. Only the 9% progresses to invasive squamous cell carcinoma. It appears in several forms and presents multiple vascular dilatations. Primary corneal epithelial dysplasia is a rare form of corneal-epithelial intraepithelial neoplasia. We present a clinical case, confirmed by anatomopathologic studies. In the present study we observed a satisfactory response after one month of topical treatment with 5FU, with no side effects. Follow-up for three years has shown no signs of recurrence.


REFERENCES

  1. Fukuoka H, Kawasaki S, Yokoi N, Yamasaki K, Kinoshita S. Cytopathological Features of a Severe Type of Corneal Intraepithelial Neoplasia. Case Rep Ophthalmol. 2016;7(1):253-61. DOI: 10.1159/0004459371.

  2. De la Campa Jiménez JA, O´Shea Cuevas GJ. Eficacia del tratamiento tópico con interferón alfa-2b en el carcinoma escamoso de la superficie ocular. Reporte de caso. Investigación materno infantil. 2016 [acceso: 30/09/2021];8(3):85-88 Disponible: https://www.medigraphic.com/pdfs/imi/imi-2016/imi163b.pdf2.

  3. Warren N, Mercer RN, Haddad J, Magrath G, Rocha KM. Corneal melt in conjunctival intraepithelial neoplasia. Am J Ophthalmol Case Rep. 2020;19:100689. DOI: 10.1016/j.ajoc.2020.1006893.

  4. Mirzayev I, Gündüz AK, Özalp Ates FS, Özcan G, Isik MU. Factors affecting recurrence after surgical treatment in cases with ocular surface squamous neoplasia. Int J Ophthalmol. 2019;12(9):1426-1431. DOI: 10.18240/ijo.2019.09.094.

  5. Morii T, Sumiolka T, Izutani-Kitano A, Takada Y, Okada Y, Kao W, et al. A case of solitary nonvascularized corneal epitelial displasia. Case Rep Ophthalmol Med. 2016 [acceso 30/09/2021]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794595/5.

  6. Rocha-de-Lossada C, Alba-Linero C, Borroni D, Rachwani-Anil R, Zamorano-Martín F, Rodríguez-Calvo-de-Mora M. Relapsed ocular squamous surface neoplasia treated with topical interferon alfa-2b. Rom J Ophthalmol. 2020 [acceso: 30/09/2021];64(1):62-65. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141926/6.

  7. Murcia López A, Borrás Blasco J, Alvarado Valero MC, Navarro Ruiz A, González Delgado M, Martínez Toldos JJ. Tratamiento farmacológico de la neoplasia corneal y conjuntival. Farm Hosp. 2005 [acceso: 30/09/2021];29:126-33. Disponible en: https://in.booksc.eu/book/14302843/ae68ba7.

  8. Kaliki S, Singh S, Iram S, Tripuraneni D. Recombinant interferon alpha 2b for ocular surface squamous neoplasia: An efficient and cost-effective treatment modality in Asian Indian patients. Indian J Ophthalmol. 2016;64(10):702-09. DOI: 10.4103/0301-4738.1950108.

  9. FIp MH, Tat L, Coroneo MT. The treatment of recurrent conjunctival and corneal intraepithelial neoplasia with interferon alfa-2b and retinoic acid: ~9 years' follow-up on tumor control. Ocul Surf. 2020;18(3):354-359. DOI: 10.1016/j.jtos.2020.04.0049.

  10. Cabrera RAC, Galbán LTM. Tratamiento de la neoplasia intraepitelial córneoconjuntival. Presentación de un paciente. Acta Med Cent. 2013 [acceso 30/09/2021];7(2). Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=4289410.

  11. Nanji AA, Sayyad FE, Karp CL. Topical chemotherapy for ocular surface squamous neoplasia. Curr Opin Ophthalmol. 2013;24(4):336-42. DOI: 10.1097/ICU.0b013e3283622a1311.

  12. Nanji AA, Moon CS, Galor A, Sein J, Oellers P, Karp CL. Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications. Ophthalmology. 2014;121(5):994-1000 DOI: 10.1016/j.ophtha.2013.11.01712.




2020     |     www.medigraphic.com